Roth Capital Has Negative Outlook for ZVRA FY2029 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities researchers at Roth Capital reduced their FY2029 earnings estimates for shares of Zevra Therapeutics in a research report issued on Tuesday, March 11th. Roth Capital analyst J. Aschoff now forecasts that the company will earn $2.05 per share for the year, down from their prior estimate of $2.26. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share.

ZVRA has been the subject of a number of other reports. Canaccord Genuity Group upped their price objective on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price objective on shares of Zevra Therapeutics in a research report on Wednesday. Guggenheim upped their price objective on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research report on Thursday. Finally, Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $22.14.

Zevra Therapeutics Price Performance

ZVRA stock opened at $7.94 on Thursday. The company has a 50 day simple moving average of $7.93 and a 200 day simple moving average of $8.14. The stock has a market cap of $423.81 million, a price-to-earnings ratio of -4.03 and a beta of 1.98. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.76. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). The company had revenue of $12.00 million for the quarter, compared to analyst estimates of $8.93 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%.

Insider Buying and Selling at Zevra Therapeutics

In other news, CEO Neil F. Mcfarlane sold 61,273 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $481,605.78. Following the completion of the sale, the chief executive officer now directly owns 222,060 shares in the company, valued at $1,745,391.60. This represents a 21.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO R. Laduane Clifton sold 11,000 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $86,460.00. Following the sale, the chief financial officer now owns 51,361 shares of the company’s stock, valued at approximately $403,697.46. This trade represents a 17.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 85,773 shares of company stock worth $674,176. 2.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zevra Therapeutics

Several large investors have recently modified their holdings of ZVRA. Vestal Point Capital LP bought a new position in Zevra Therapeutics during the third quarter worth $3,644,000. Geode Capital Management LLC boosted its stake in Zevra Therapeutics by 14.2% during the third quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock worth $7,246,000 after acquiring an additional 129,600 shares in the last quarter. Barclays PLC boosted its stake in Zevra Therapeutics by 292.6% during the third quarter. Barclays PLC now owns 57,599 shares of the company’s stock worth $399,000 after acquiring an additional 42,926 shares in the last quarter. Propel Bio Management LLC bought a new position in Zevra Therapeutics during the third quarter worth $1,248,000. Finally, Simplify Asset Management Inc. bought a new position in Zevra Therapeutics during the third quarter worth $833,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.